SkinBioTherapeutics PLC (SBTX) — Cash Flow-to-Debt Ratio
SkinBioTherapeutics PLC (SBTX) has a Cash Flow-to-Debt Ratio of -0.18x as of June 2025, meaning its operating cash flow of GBX-494.84K could theoretically repay 0% of its total liabilities (GBX2.71 Million) in one year. See SkinBioTherapeutics PLC free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SkinBioTherapeutics PLC Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for SkinBioTherapeutics PLC across 10 annual periods. For the full cash flow conversion analysis, see SkinBioTherapeutics PLC operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for SkinBioTherapeutics PLC (2016–2025)
Year-by-year debt coverage analysis for SkinBioTherapeutics PLC. Check SBTX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.48x | GBX-1.30 Million | GBX2.71 Million | ▲ +60.5% |
| 2024 | -1.21x | GBX-2.73 Million | GBX2.25 Million | ▲ +72.5% |
| 2023 | -4.41x | GBX-2.65 Million | GBX599.34K | ▼ -0.7% |
| 2022 | -4.38x | GBX-2.67 Million | GBX609.61K | ▼ -46.5% |
| 2021 | -2.99x | GBX-1.56 Million | GBX519.67K | ▼ -2.2% |
| 2020 | -2.93x | GBX-892.14K | GBX304.83K | ▲ +75.1% |
| 2019 | -11.77x | GBX-1.43 Million | GBX121.33K | ▼ -269.0% |
| 2018 | -3.19x | GBX-667.75K | GBX209.29K | ▲ +37.9% |
| 2017 | -5.14x | GBX-609.70K | GBX118.66K | ▼ -14711.9% |
| 2016 | -0.03x | GBX-1.17K | GBX33.64K | — |